Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Spain / NCT06727487
Recruiting Not applicable

OvS Breast: Ovarian Suppression in Breast Cancer Interventions

NCT06727487 · tracked via the Priya Life Science Spain tracker
Phase
Not applicable
Started
2024-11-15
Last updated
2024-12-11

Condition(s) studied

Breast Neoplasms

Investigational drug(s) / intervention(s)

Basic recommendationsPhysical exerciseNutritional advicePsycho-oncological support

Basic recommendations: Daily basis activity counseling by WHO recommendations

Physical exercise: A complete program of active physical exercise of medium and high intensity

Nutritional advice: A complete program of nutritional counseling

Psycho-oncological support: A program related with a patient Psycho-oncological follow-up

Study summary

The goal of this clinical trial is to compare a combined intervention based on physical exercise, nutritional control, and individualized psycho-oncological support can achieve weight control and maintain adequate body composition in premenopausal women with localized BC with ER and/or PR expression who receive aLHRH in combination with TAM or AI as part of adjuvant treatment.

The study's primary objectives are to evaluate the impact of the combined intervention on weight reduction and favorable modification of body composition in terms of reduction in body fat and increase in lean mass.

The secondary objectives aim to evaluate the impact of the combined intervention program on CRF, heart rate (HR), capillary lactate levels, upper and lower body strength, physical functionality, and patient-reported outcomes (PROs). (exercise level, asthenia, self-perception, anxiety and depression), blood count and biochemistry values that could be modified, nutritional situation, and side effects of treatments.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
45 Years
Healthy volunteers
No
Inclusion Criteria: * Women who have reached the age of majority and up to 45 years of age. * Premenopausal status is defined clinically as a patient who maintains menstruation prior to the start of chemotherapy treatment if this has taken place. * Confirmed histological diagnosis of infiltrating breast carcinoma with expression of ER and/or RP stage I to III. * Loco-regional treatment with surgery and radiotherapy, if any, completed. * Adjuvant treatment with drugs that suppress ovarian function (aLHRH) is ongoing and expected to be maintained for at least 4 months at the beginning of the study. * Functional status according to the Eastern Cooperative Oncology Group (ECOG) scale 0-1. * Ability to understand and agree to the Informed Consent in writing. Exclusion Criteria: * Presence of medical contraindications to perform physical exercise. * Presence of any of the American Thoracic Society (ATS) criteria to perform a cardiovascular capacity test. * Presence of active neoplastic disease: metastatic breast cancer or other active tumor diseases. * Pregnancy or breastfeeding. * Alcohol or other drug abuse (excluding smoking).

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
Universidad Pontificia Comillas Madrid Spain Recruiting
Hospital General Universitario Gregorio Marañón Madrid Spain Recruiting

More Universidad Pontificia Comillas trials in Spain

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06727487 on ClinicalTrials.gov ↗ ← All trials in Spain